PEGylation

Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout

Retrieved on: 
Donnerstag, Juni 13, 2024
EDT, Patient, Doctor of Science, Charles University, PEGylation, Fabry disease, Gout, FESC, Protalix BioTherapeutics, University of Utah, University, Vaccine

CARMIEL, Israel, June 13, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will host an in-person investor day at the Lotte Palace New York Hotel in New York on Wednesday, June 26, 2024 at 8:30 a.m. Eastern Daylight Time (EDT).

Key Points: 
  • The investor day will feature presentations by the following key opinion leaders:
    Aleš Linhart, DSc, FESC (Charles University, Prague), who will discuss the treatment landscape for Fabry disease and perspectives on Elfabrio® (pegunigalsidase alfa), a plant cell-expressed PEGylated recombinant α-Galactosidase-A enzyme approved for adult patients with Fabry disease.
  • Naomi Schlesinger, MD (University of Utah), who will discuss the current treatment landscape for uncontrolled gout and top-line results from the First-in-Human Phase I single ascending dose clinical trial of PRX-115, a plant cell-expressed recombinant PEGylated uricase.
  • In addition, the event will include a corporate overview and strategy presentation by Dror Bashan, Protalix's President and Chief Executive Officer.
  • A live question and answer session will follow the formal presentations.

HighField Biopharmaceuticals ASCO 2024 Poster Presentation Shows HFK1, a Unique Immunoliposome May Improve Clinical Outcomes over Antibody Drug Conjugates

Retrieved on: 
Dienstag, Mai 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Diabetes, Clinical Trials, Patient, HER2, Safety, PEGylation, Cancer, Spacecraft, ASCO, PLD, Poster, Society, Pharmaceutical industry

The poster presentation describes preliminary findings from the company’s Phase 1a study of HFK1 for HER2 low expression cancers.

Key Points: 
  • The poster presentation describes preliminary findings from the company’s Phase 1a study of HFK1 for HER2 low expression cancers.
  • The patient has been treated with HFK1 for more than five months with no dose-limiting toxicity and stable disease.
  • The clinical and preclinical data, which will be presented by HighField CEO and Scientific Founder Yuhong Xu, Ph.D., also includes study results comparing HFK1 to other antibody drug conjugates (ADCs) and PEGylated liposomal doxorubicin (PLD).
  • HighField’s immunoliposomes represent a new generation of targeted chemotherapy drugs following the success of antibody drug conjugates (ADCs).

Vasomune Therapeutics Receives US FDA Fast Track Designation for Novel Investigational Medicine AV-001

Retrieved on: 
Dienstag, Mai 28, 2024
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, Food, FDA, Therapy, Safety, PEGylation, Fast Track, National Research Council, Mortality, Pneumonia, Pharmaceutical industry

Vasomune Therapeutics, Inc., has announced today that the US Food and Drug Administration (FDA) granted Fast Track designation for AV-001 for the prevention or treatment of moderate-to-severe ARDS in patients hospitalized with viral and/or bacterial respiratory infections.

Key Points: 
  • Vasomune Therapeutics, Inc., has announced today that the US Food and Drug Administration (FDA) granted Fast Track designation for AV-001 for the prevention or treatment of moderate-to-severe ARDS in patients hospitalized with viral and/or bacterial respiratory infections.
  • AV-001 is a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor which plays a critical role in vascular stability, barrier integrity and endothelial quiescence, particularly within the pulmonary space.
  • Data from the Phase 1 study established safety, a pharmacokinetic profile amenable to once-daily dosing and Tie2 activation demonstrating strong on-target activity.
  • “Vasomune is focused on the persisting unmet needs of people grappling with ARDS and other diseases driven by vascular endothelial instability,” said Dr. Brian Jahns, President and Chief Operating Officer.

World PEGylated Proteins Analysis Report 2023-2028: Increasing Utilization of Protein Drugs in Hematology and Oncology Bodes Well for the Market - ResearchAndMarkets.com

Retrieved on: 
Freitag, Mai 10, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Environment, ESG, Insight, PEGylation

The "PEGylated Proteins Market 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "PEGylated Proteins Market 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • This report highlights the current and future market potential of PEGylated proteins and provides a detailed analysis of the drivers, restraints, and opportunities in this market.
  • The report also surveys the competitive environment for PEGylated proteins, including coverage of the pipeline activities adopted by players in this market, and it includes market projections for 2028.
  • In this report, the global market for PEGylated proteins market is segmented into four regions: North America, Europe, Asia-Pacific and the Rest of the World.

Vasomune Therapeutics Announces Poster Presentation at the American Thoracic Society International Conference

Retrieved on: 
Montag, Mai 6, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Clinical Trials, TEK tyrosine kinase, ATS, Pneumonia, Safety, SARS-CoV-2, Pharmacokinetics, Conference, PEGylation, Acute respiratory distress syndrome, C40, Patient, National Research Council Canada, American Thoracic Society, Therapy, Risk, Infection, Pharmaceutical industry

Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of AV-001 for the treatment of diseases associated with vascular dysfunction, today announced that the Company will present a Late-Breaking scientific poster at the upcoming 2024 American Thoracic Society (ATS) International Conference taking place May 17-22, 2024, at the Manchester Grand Hyatt, San Diego, CA.

Key Points: 
  • Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of AV-001 for the treatment of diseases associated with vascular dysfunction, today announced that the Company will present a Late-Breaking scientific poster at the upcoming 2024 American Thoracic Society (ATS) International Conference taking place May 17-22, 2024, at the Manchester Grand Hyatt, San Diego, CA.
  • Vasomune’s lead drug candidate AV-001, codeveloped with AnGes Inc, is a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor.
  • Activation of the Tie2 receptor plays a critical role in promoting vascular stability, barrier integrity and endothelial quiescence.
  • “Vasomune is grateful to the National Research Council Canada for grant #IRAP-965762 which supported the Phase 1 study.

American Thoracic Society Selects Vasomune Therapeutics, Inc., to Present the AV-001 Development Update at the 2024 Respiratory Innovation Summit

Retrieved on: 
Montag, April 15, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, TEK tyrosine kinase, H3N2, Pneumonia, Safety, Sepsis, Survival, HVR, Conference, Stroke, PEGylation, Disease, Acute kidney injury, Therapy, Patient, RIS, Death, American Thoracic Society, Vascular dementia, Infection

Activation of this receptor plays a critical role in vascular stability, barrier integrity and endothelial quiescence, particularly within the pulmonary space.

Key Points: 
  • Activation of this receptor plays a critical role in vascular stability, barrier integrity and endothelial quiescence, particularly within the pulmonary space.
  • Vasomune’s Scientific co-founder, Dr. Harold Kim, will speak on May 18th, at 11:30 AM PT, at the Manchester Grand Hyatt, San Diego, CA.
  • “We are extremely excited to be invited to present our work at the Respiratory Innovation Summit during the American Thoracic Society 2024 Conference.
  • Join Dr. Kim at the Respiratory Innovation Summit to learn how Vasomune Therapeutics has brought together decades of research to create AV-001, a clinical-stage candidate for the treatment of diseases associated with vascular dysfunction.

Modified Release Neurology Therapeutics Report 2024 - Neurology Therapeutics Advance with Modified Release Formulation - ResearchAndMarkets.com

Retrieved on: 
Montag, Februar 19, 2024
Biotechnology, Pharmaceutical, Health, Neurology, Incidence, Injection (medicine), PEGylation, Marketing, Drug development, Polymer, Knowledge, Risk, Prevalence, ChromeOS, Patent, Patient, Data mining, Economics, Genomics, Taste, NDA, Research, Pharmaceutical industry

The "Modified Release Neurology Therapeutics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Modified Release Neurology Therapeutics" report has been added to ResearchAndMarkets.com's offering.
  • Data mining technologies, combined with data from genomics, combinational chemistry and outcome-based medicine, provide opportunities to search for new patterns.
  • The majority of projects/products are marked by a contractual relationship between the formulation IP developer/holder and the drug developer.
  • Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended release profiles.

Cayman Chemical Introduces LipidLaunch™, Expands Portfolio of Lipid Nanoparticle Research Tools to Support Advances in RNA Therapies

Retrieved on: 
Dienstag, Februar 20, 2024
Lipid, Messenger, PEGylation, ANN, Catalog, COVID-19 vaccine, RNA, COVID-19, Chemical substance, Sterol, Research, Cancer, Sand

ANN ARBOR, Mich., Feb. 20, 2024 /PRNewswire-PRWeb/ -- Cayman Chemical, a leading supplier of research tools for lipid nanoparticles (LNPs), announced today the introduction of LipidLaunch™ research-ready LNPs and reagent kits. The LipidLaunch™ product line is the latest addition to the company's portfolio of LNP research tools and reflects the company's legacy of providing high-quality lipids for academic, pharma, and biotech researchers worldwide.

Key Points: 
  • Cayman Chemical introduces the latest addition to the company's portfolio of lipid nanoparticle (LNP) research tools for academic, pharma, and biotech researchers worldwide.
  • ANN ARBOR, Mich., Feb. 20, 2024 /PRNewswire-PRWeb/ -- Cayman Chemical, a leading supplier of research tools for lipid nanoparticles (LNPs), announced today the introduction of LipidLaunch™ research-ready LNPs and reagent kits.
  • The LipidLaunch™ product line is the latest addition to the company's portfolio of LNP research tools and reflects the company's legacy of providing high-quality lipids for academic, pharma, and biotech researchers worldwide.
  • Cayman's LipidLaunch™ products support LNP research and development from discovery to bioanalysis with a range of purpose-built solutions.

Global Lipid Nanoparticle Manufacturing Market 2023-2035: Partnerships Surge in Lipid Nanoparticle Manufacturing as Moderna Collaborates with IBM for Cutting-Edge LNPs - ResearchAndMarkets.com

Retrieved on: 
Montag, Februar 12, 2024
Technology, Biotechnology, Nanotechnology, Health, Molecule, CMO, Infection, Growth, RNA, Phospholipid, Liposome, Solubility, Organization, Absorption, Integration, Therapy, Type, Levidian Nanosystems, Small RNA, Ionization, DNA, Partnership, Creative Biolabs, CMOS, Permeability, Sphingolipid, CDMO, SaRNA, Dicarboxylic acid, Antigen, Research, Emergent, Acquisition, Lipid, Messenger, PEGylation, IBM, Geography, Risk, Fresenius (company), Fujifilm, Triglyceride, Element, MicroRNA, Acuitas Therapeutics, Vaccine

This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.

Key Points: 
  • This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.
  • The report features an extensive study of the current market landscape, market size and future opportunities within the lipid nanoparticle manufacturing market, during the given forecast period.
  • Key takeaways of the lipid nanoparticle manufacturing (services and technologies) market report are briefly discussed below.
  • An in-depth analysis of the factors that can impact the growth of lipid nanoparticle manufacturing market.

ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)

Retrieved on: 
Montag, Februar 5, 2024
MYCN, Toxicity, SAN, Neoplasm, NCI, Glomus tumor, SN-38, DNA, Cmax, SLFN11, Clinical trial, Gene, Biomarker, Cell division, Patient, Safety, Irinotecan, Pros, Central nervous system, MYC, PEGylation, CNS, Phase, Medulloblastoma, TTY, Cancer, Bangladesh Technical Education Board, Ependymoma, Pharmaceutical industry

National Institutes of Health’s NCI investigators Dr. Marta Penas-Prado and Dr. Mark Gilbert are conducting the trial.

Key Points: 
  • National Institutes of Health’s NCI investigators Dr. Marta Penas-Prado and Dr. Mark Gilbert are conducting the trial.
  • High levels of MYC drive oncogenesis in many cancers and induce DNA changes leading to the formation of “topoisome complexes”.
  • The NCI trial will assess whether PLX038 is safe and efficacious in primary CNS tumors driven by MYC or MYCN amplifications.
  • For patients interested in enrolling in this clinical trial, please call NCI’s toll-free number: 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615); visit the website: https://trials.cancer.gov; and/or email: [email protected].